Pharma stocks advanced on optimism that rival Pfizer Inc.’s pricing agreement opens the way for others to strike similar deals.

AstraZeneca up nearly 7%; Moderna up 5%; Sanofi up 4%; Novavax, Eli Lilly up over 3%; Novo, Pfizer up over 2%.

Pfizer secured a three-year grace period from President Donald Trump’s promised tariffs on pharmaceuticals in a deal announced Tuesday. The agreement gives others a blueprint to gain some respite, analysts said.

Pfizer agreed to sell some drugs at a 50% average discount on a direct-to-consumer website called TrumpRx, an initiative intended to allow Americans to pay for prescriptions at discounted rates negotiated by the government. The US pharma market, the biggest in the world, is crucial for European drugmakers.